Abstract:Ca2+ antagonist drugs are widely used in therapy of cardiovascular disorders. Three chemical classes of drugs bind to three separate, but allosterically interacting, receptor sites on CaV1.2 channels, the most prominent voltage-gated Ca2+ (CaV) channel type in myocytes in cardiac and vascular smooth muscle. The 1,4-dihydropyridines are used primarily for treatment of hypertension and angina pectoris and are thought to act as allosteric modulators of voltage-dependent Ca2+ channel activation, whereas phenylalkylamines and benzothiazepines are used primarily for treatment of cardiac arrhythmias and are thought to physically block the pore. The structural basis for the different binding, action, and therapeutic uses of these drugs remains unknown. Here we present crystallographic and functional analyses of drug binding to the bacterial homotetrameric model CaV channel CaVAb, which is inhibited by dihydropyridines and phenylalkylamines with nanomolar affinity in a state-dependent manner. The binding site for amlodipine and other dihydropyridines is located on the external, lipid-facing surface of the pore module, positioned at the interface of two subunits. Dihydropyridine binding allosterically induces an asymmetric conformation of the selectivity filter, in which partially dehydrated Ca2+ interacts directly with one subunit and blocks the pore. In contrast, the phenylalkylamine Br-verapamil binds in the central cavity of the pore on the intracellular side of the selectivity filter, physically blocking the ion-conducting pathway. Structure-based mutations of key amino-acid residues confirm drug binding at both sites. Our results define the structural basis for binding of dihydropyridines and phenylalkylamines at their distinct receptor sites on CaV channels and offer key insights into their fundamental mechanisms of action and differential therapeutic uses in cardiovascular diseases.

Seeking the Exclusive Binding Region of Phenylalkylamine Derivatives on Human T‐type Calcium Channels Via Homology Modeling and Molecular Dynamics Simulation Approach

Phenylalkylamines in calcium channels: computational analysis of experimental structures

Phenylakylamines in Calcium Channels. Experimental Structures and Computational Models

Molecular determinants of drug binding and action on L-type calcium channels

Binding Mechanisms Of 1,4-Dihydropyridine Derivatives To L-Type Calcium Channel Ca(V)1.2: A Molecular Modeling Study

Structural basis for human Ca v 3.2 inhibition by selective antagonists

Molecular Basis for Ligand Modulation of a Mammalian Voltage-Gated Ca2+ Channel

Homology Modeling Identifies C-Terminal Residues That Contribute to the Ca2+ Sensitivity of A Bkca Channel

Molecular Simulations Study of Novel 1,4-Dihydropyridines Derivatives with A High Selectivity for Cav3.1 Calcium Channel

Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs

Structure, gating, and pharmacology of human Ca V 3.3 channel

Determination of the Μ-Conotoxin PIIIA Specificity Against Voltage-Gated Sodium Channels from Binding Energy Calculations.

Structural Basis for Human Cav3.2 Inhibition by Selective Antagonists

Structural basis for modulation of human Na V 1.3 by clinical drug and selective antagonist

Identification of the Benzyloxyphenyl Pharmacophore: A Structural Unit That Promotes Sodium Channel Slow Inactivation

Characterization of Binding Site of Closed-State KCNQ1 Potassium Channel by Homology Modeling, Molecular Docking, and Pharmacophore Identification

A comprehensive search for calcium binding sites critical for TMEM16A calcium-activated chloride channel activity

Insight into the binding model of new antagonists of kappa receptor using docking and molecular dynamics simulation

Atomistic modeling and molecular dynamics analysis of human CaV1.2 channel using external electric field and ion pulling simulations

Design, Synthesis, And Pharmacological Evaluation Of Analogues Derived From The Plev Tetrapeptide As Protein-Protein Interaction Modulators Of Voltage-Gated Sodium Channel 1.6

Homology modeling and application of 3 D structure of Cav1.2 channel